Solid Tumor Completed Phase 1 Trials for Pazopanib (DB06589)
Also known as: Cancer - Solid Tumors / Solid Tumour / Solid Tumours / Tumor, Solid / Solid Neoplasms / Solid tumour/cancer / Solid Cancers / Cancer: Solid Tumors / Neoplasms, Solid Tumor / Cancer, Solid Tumor / Tumors, Solid / Solid Tumor Cancer / Solid Tumors or Cancers / Solid Tumors / Solid Neoplasm / Cancer (Solid Tumors) / Solid Tumor Neoplasms / Solid Tumor Cancers / Solid Cancer / Neoplasm / Neoplasm (morphologic abnormality) / Neoplasms of unspecified behavior / Neoplasms NOS / Neoplasms NOS (disorder) / [M]Neoplasms NOS (morphologic abnormality) / Neoplasm (NOS) / Tumor / Neoplasm NOS / Tumour / Tumour NOS / Neoplasms / Tumour, NOS / Tumor NOS / Neoplasm, NOS / Tumor, NOS / Neoplasms benign, malignant and unspecified (incl cysts and polyps)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0030180 (Solid Tumor) | Completed | 1 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT00732420 | Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors | Screening | |
| NCT01468922 | Pazopanib and ARQ 197 for Advanced Solid Tumors | Treatment | |
| NCT01184326 | Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer | Treatment | |
| NCT01543763 | Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors | Treatment | |
| NCT01202032 | Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors | Treatment | |
| NCT02009449 | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | Treatment | |
| NCT01438554 | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | Other | |
| NCT02303028 | Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours | Treatment | |
| NCT01485042 | Dose Escalation Study of Pazopanib Plus TH-302 | Other | |
| NCT01165385 | Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors | Treatment | |
| NCT01430572 | Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients | Treatment | |
| NCT01072890 | Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors | Treatment | |
| NCT00929903 | Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment | Treatment |